Roche’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions
Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on OCREVUS…
Modern Dental Group Announces 2026 Interim Results
Merdeka Gold Delivers Strong Q2 Production Ramp-Up as Pani Gold Mine Advances Toward Full-year Growth
Nissin Foods Announces 2026 Interim Results
The World’s Leading Minds in Biotechnology Will Meet in Riyadh This September
Overseas Growth Gathers Momentum as CanSinoBIO’s Global Strategy Unlocks New Opportunities